Screener
Monte Rosa Therapeutics, Inc. GLUE Maintenance — One Time Upfront Payment
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept glue:OneTimeUpfrontPayment.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210358
The Company has concluded that the transaction price at inception is $180 million, which consists of the $120 million upfront payment and $60 million of option maintenance payments due over the course of the contract term. The Company has identified the following performance obligations in the contract:
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s maintenance — one time upfront payment?
- Monte Rosa Therapeutics, Inc. (GLUE) reported maintenance — one time upfront payment of $60M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s maintenance — one time upfront payment changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s maintenance — one time upfront payment increased by 300.0% year-over-year, from $15M to $60M.
- What does maintenance — one time upfront payment mean?
- This metric represents non-recurring, lump-sum payments received from strategic partners or collaborators at the inception of a licensing or development agreement. It reflects the immediate cash inflow associated with granting access to proprietary technology platforms or specific drug candidates within the maintenance segment. Such payments are critical indicators of the commercial validation of the company's research pipeline and provide non-dilutive capital to support ongoing operational activities.
Ask your AI about Monte Rosa Therapeutics, Inc.'s maintenance — one time upfront payment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude